1
|
Jackman DM and Johnson BE: Small-cell lung
cancer. Lancet. 366:1385–1396. 2005. View Article : Google Scholar : PubMed/NCBI
|
2
|
Govindan R, Page N, Morgensztern D, et al:
Changing epidemiology of small-cell lung cancer in the United
States over the last 30 years: analysis of the surveillance,
epidemiologic, and end results database. J Clin Oncol.
24:4539–4544. 2006.PubMed/NCBI
|
3
|
Turrisi AT III, Kim K, Blum R, et al:
Twice-daily compared with once-daily thoracic radiotherapy in
limited small-cell lung cancer treated concurrently with cisplatin
and etoposide. N Engl J Med. 340:265–271. 1999. View Article : Google Scholar
|
4
|
Takada M, Fukuoka M, Kawahara M, et al:
Phase III study of concurrent versus sequential thoracic
radiotherapy in combination with cisplatin and etoposide for
limited-stage small-cell lung cancer: results of the Japan Clinical
Oncology Group Study 9104. J Clin Oncol. 20:3054–3060. 2002.
View Article : Google Scholar
|
5
|
Alix-Panabières C, Riethdorf S and Pantel
K: Circulating tumor cells and bone marrow micrometastasis. Clin
Cancer Res. 14:5013–5021. 2008.
|
6
|
Tanaka F, Yoneda K, Kondo N, et al:
Circulating tumor cell as a diagnostic marker in primary lung
cancer. Clin Cancer Res. 15:6980–6986. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Rolle A, Günzel R, Pachmann U, Willen B,
Höffken K and Pachmann K: Increase in number of circulating
disseminated epithelial cells after surgery for non-small cell lung
cancer monitored by MAINTRAC(R) is a predictor for relapse: A
preliminary report. World J Surg Oncol. 3:182005. View Article : Google Scholar
|
8
|
Taki M, Kagawa S, Nishizaki M, et al:
Enhanced oncolysis by a tropism-modified telomerase-specific
replication-selective adenoviral agent OBP-405 (‘Telomelysin-RGD’).
Oncogene. 24:3130–3140. 2005.PubMed/NCBI
|
9
|
Fujiwara T, Kagawa S, Kishimoto H, et al:
Enhanced antitumor efficacy of telomerase-selective oncolytic
adenoviral agent OBP-401 with docetaxel: preclinical evaluation of
chemovirotherapy. Int J Cancer. 119:432–440. 2006. View Article : Google Scholar
|
10
|
Greider CW and Blackburn EH:
Identification of a specific telomere terminal transferase activity
in Tetrahymena extracts. Cell. 43:405–413. 1985. View Article : Google Scholar : PubMed/NCBI
|
11
|
Collins K and Mitchell JR: Telomerase in
the human organism. Oncogene. 21:564–579. 2002. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kim NW, Piatyszek MA, Prowse KR, et al:
Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar
|
13
|
Shay JW and Wright WE: Telomerase activity
in human cancer. Curr Opin Oncol. 8:66–71. 1996. View Article : Google Scholar
|
14
|
Nakayama J, Tahara H, Tahara E, et al:
Telomerase activation by hTRT in human normal fibroblasts and
hepatocellular carcinomas. Nat Genet. 18:65–68. 1998. View Article : Google Scholar
|
15
|
Kim SJ, Masago A, Tamaki Y, et al: A novel
approach using telomerase-specific replication-selective adenovirus
for detection of circulating tumor cells in breast cancer patients.
Breast Cancer Res Treat. 128:765–773. 2011. View Article : Google Scholar
|
16
|
Ito H, Inoue H, Sando N, et al: Prognostic
impact of detecting viable circulating tumour cells in gastric
cancer patients using a telomerase-specific viral agent: a
prospective study. BMC Cancer. 12:3462012. View Article : Google Scholar
|
17
|
Yabusaki M, Sato J, Kohyama A, et al:
Detection and evaluation of circulating tumor cells in digestive
system cancers using telomerase-specific adenovirus. In: Proceeding
of 71st annual meeting of the Japan Cancer Association abst; 3395.
2012
|
18
|
Takakura M, Kyo S, Nakamura M, et al:
Circulating tumour cells detected by a novel adenovirus-mediated
system may be a potent therapeutic marker in gynaecological
cancers. Br J Cancer. 107:448–454. 2012. View Article : Google Scholar
|
19
|
Hiltermann TJ, Pore MM, van den Berg A, et
al: Circulating tumor cells in small-cell lung cancer: a predictive
and prognostic factor. Ann Oncol. 23:2937–2942. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Naito T, Tanaka F, Ono A, et al:
Prognostic impact of circulating tumor cells in patients with small
cell lung cancer. J Thorac Oncol. 7:512–519. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Hou JM, Krebs MG, Lancashire L, et al:
Clinical significance and molecular characteristics of circulating
tumor cells and circulating tumor microemboli in patients with
small-cell lung cancer. J Clin Oncol. 30:525–532. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Sieuwerts AM, Kraan J, Bolt J, et al:
Anti-epithelial cell adhesion molecule antibodies and the detection
of circulating normal-like breast tumor cells. J Natl Cancer Inst.
101:61–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig
R and Kasimir-Bauer S: Stem cell and epithelial-mesenchymal
transition markers are frequently overexpressed in circulating
tumor cells of metastatic breast cancer patients. Breast Cancer
Res. 11:R462009. View
Article : Google Scholar
|
26
|
Bonnomet A, Brysse A, Tachsidis A, et al:
Epithelial-to-mesenchymal transitions and circulating tumor cells.
J Mammary Gland Biol Neoplasia. 15:261–273. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Lu J, Fan T, Zhao Q, et al: Isolation of
circulating epithelial and tumor progenitor cells with an invasive
phenotype from breast cancer patients. Int J Cancer. 126:669–683.
2010. View Article : Google Scholar : PubMed/NCBI
|